Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial

Background: Biomarker/s able to detect minimal residual disease (MRD) after breast cancer (BC) surgery are needed to aid optimal systemic therapy. We aimed at investigating the feasibility of using circulating tumor DNA (ctDNA) to early detect MRD in plasma samples collected during the follow-up of patients (pts) with early BC. Methods: Forty BC pts undergoing surgery with curative intent and regular follow-up for a minimum of 13 years were...